May 22, 2018

Pershing Square Sohn Prize-Mark Foundation Fellow Announced

Computational Biologist Awarded Prestigious Research Prize

In partnership with the Pershing Square Sohn Cancer Research Alliance, The Mark Foundation is pleased to announce that Dr. Benjamin Greenbaum has been named the 2018 Pershing Square Sohn Prize-Mark Foundation Fellow. This award will support Dr. Greenbaum’s research, in which he uses methods from math and physics to analyze highly complex data to understand better immunotherapy responses so that more patients can be successfully treated.

Dr. Greenbaum is an Assistant Professor in the Departments of Medicine, Oncological Sciences, and Pathology at the Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute. His research will use a new computational approach to modeling tumor-immune recognition to integrate information about the tumor and its environment into improved predictions of response to immunotherapy.

“The prize will allow us to integrate our understandings of the roles of neoantigens in tumor evolution and responses to immunotherapy with our understanding of how a tumor’s environment shapes its evolution,” said Dr. Greenbaum.

Learn more about Dr. Greenbaum’s Pershing Square Sohn-Mark Foundation Fellowship project here.


About The Mark Foundation for Cancer Research

The Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by integrating discoveries in biology with innovative technology. Launched in 2017, The Mark Foundation pursues its mission by funding a global portfolio of groundbreaking research carried out by individual investigators, multi-investigator teams, and inter-institutional collaborations.

Recognizing the obstacles that can prevent scientific advances from improving patient outcomes, The Mark Foundation maintains a nimble, high-impact approach to funding research that encompasses grants for basic and translational cancer research, as well as venture philanthropy investment in companies that bridge the gap between the bench and the bedside. For more information, visit:

About The Pershing Square Sohn Cancer Research Alliance

The Pershing Square Sohn Cancer Research Alliance was formed in 2013 through a $25 million commitment by Bill and Karen Ackman and The Pershing Square Foundation, which partnered with The Sohn Conference Foundation.  The Alliance is dedicated to playing a catalytic role in accelerating cures for cancer by supporting innovative cancer research and by facilitating collaborations between academia and industry.  Annually, the Alliance awards The Pershing Square Sohn Prize to young New York based scientists who are engaged in cutting-edge cancer research. For more information, visit



Back to all news